The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Official Title: A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Study ID: NCT04084951
Brief Summary: This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune checkpoint inhibitors in HLA-A\*02+ patients with recurrent, locally advanced or metastatic human papillomavirus strain 16 positive (HPV16+) solid tumors. The study includes patients with anal, rectal, cervical, head and neck, penile, vulvar, or vaginal cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
HonorHealth, Scottsdale, Arizona, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
University of Colorado Anschutz Cancer Pavillion, Aurora, Colorado, United States
University of Kansas Cancer Center, Kansas City, Kansas, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
The Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Providence Cancer Institute, Portland, Oregon, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
University Hospital Cologne, Clinic I for Internal Medicine, Cologne, , Germany